Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Gadoterate meglumine (Dotarem) is indicated for intravenous use with MRI in the brain, spine, and associated tissues to detect and visualize areas with disruption of the blood-brain barrier or abnormal vascularity.
• The information was derived from two systematic reviews/meta-analyses studies.
• Dotarem exhibits a lower prevalence of Symptoms Associated with Gadolinium Exposure (SAGE) compared to gadobenate dimeglumine and gadoteridol, indicating potentially better safety regarding SAGE-related adverse events.
• In patients with stage 4 or 5 chronic kidney disease (CKD), no cases of Nephrogenic Systemic Fibrosis (NSF) were reported following administration of Dotarem; however, it has an upper bound risk estimate higher than gadobenate dimeglumine but lower than gadobutrol and gadoteridol.
• For general populations as well as high-risk subgroups like those with advanced CKD, Dotarem shows a favorable safety profile based on the reviewed data concerning both SAGE prevalence and NSF incidence rates.
• No direct conclusions about comparative imaging effectiveness can be drawn from these studies since they focus primarily on safety outcomes rather than imaging efficacy.